These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 21300721

  • 1. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
    Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D.
    Cardiovasc Res; 2011 Jul 01; 91(1):53-61. PubMed ID: 21300721
    [Abstract] [Full Text] [Related]

  • 2. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Wiśniowska B, Mendyk A, Fijorek K, Glinka A, Polak S.
    J Appl Toxicol; 2012 Oct 01; 32(10):858-66. PubMed ID: 22761000
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG.
    Cardiovasc Res; 2003 Apr 01; 58(1):32-45. PubMed ID: 12667944
    [Abstract] [Full Text] [Related]

  • 5. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
    Di Veroli GY, Davies MR, Zhang H, Abi-Gerges N, Boyett MR.
    Am J Physiol Heart Circ Physiol; 2013 Jan 01; 304(1):H104-17. PubMed ID: 23103500
    [Abstract] [Full Text] [Related]

  • 6. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
    Marostica E, Van Ammel K, Teisman A, Boussery K, Van Bocxlaer J, De Ridder F, Gallacher D, Vermeulen A.
    J Pharmacokinet Pharmacodyn; 2015 Dec 01; 42(6):659-79. PubMed ID: 26259721
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
    DI Veroli GY, Davies MR, Zhang H, Abi-Gerges N, Boyett MR.
    J Cardiovasc Electrophysiol; 2014 Feb 01; 25(2):197-207. PubMed ID: 24118558
    [Abstract] [Full Text] [Related]

  • 10. Computational approaches to understand the adverse drug effect on potassium, sodium and calcium channels for predicting TdP cardiac arrhythmias.
    Sharifi M.
    J Mol Graph Model; 2017 Sep 01; 76():152-160. PubMed ID: 28756335
    [Abstract] [Full Text] [Related]

  • 11. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
    Lu HR, Hermans AN, Gallacher DJ.
    Br J Pharmacol; 2012 Jun 01; 166(4):1490-502. PubMed ID: 22300168
    [Abstract] [Full Text] [Related]

  • 12. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S, Wiśniowska B, Brandys J.
    J Appl Toxicol; 2009 Apr 01; 29(3):183-206. PubMed ID: 18988205
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.